Seeking Alpha
29 Jul 2026, 18:36 UTC · 4h ago
Coherus Oncology: The Catalyst Rich Period Is Here
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
29 Jul 2026, 18:36 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Coherus Oncology has multiple clinical readouts for tagmokitug and casdozokitug scheduled for H2'26 and H1'27. — Clinical trial results are primary binary catalysts for biotech valuations and can cause significant price swings.
+0.60Potential future capital raises are identified as a key risk for the company. — Equity offerings typically lead to share dilution, which is viewed negatively by current shareholders.
-0.50Loqtorzi revenues are projected to grow. — Steady commercial growth provides a fundamental valuation floor and reduces immediate cash burn.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Positive outlook due to upcoming clinical catalysts and revenue growth projections for Loqtorzi, balanced by capital raise risks.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Newsfile Corp
9h ago
